JP2022058377A - 異なる尾繊維を有する複数宿主域のバクテリオファージ - Google Patents
異なる尾繊維を有する複数宿主域のバクテリオファージ Download PDFInfo
- Publication number
- JP2022058377A JP2022058377A JP2021206315A JP2021206315A JP2022058377A JP 2022058377 A JP2022058377 A JP 2022058377A JP 2021206315 A JP2021206315 A JP 2021206315A JP 2021206315 A JP2021206315 A JP 2021206315A JP 2022058377 A JP2022058377 A JP 2022058377A
- Authority
- JP
- Japan
- Prior art keywords
- phi33
- gene
- tail fiber
- phage
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001515965 unidentified phage Species 0.000 title claims abstract description 115
- 239000000835 fiber Substances 0.000 title description 293
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 290
- 230000027455 binding Effects 0.000 claims abstract description 50
- 230000002101 lytic effect Effects 0.000 claims abstract description 49
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 45
- 241000894006 Bacteria Species 0.000 claims abstract description 41
- 230000001580 bacterial effect Effects 0.000 claims abstract description 34
- 108020003175 receptors Proteins 0.000 claims abstract description 34
- 102000005962 receptors Human genes 0.000 claims abstract description 34
- 210000004897 n-terminal region Anatomy 0.000 claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 101710166729 Tail fiber protein Proteins 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 8
- 231100000331 toxic Toxicity 0.000 claims abstract description 8
- 230000002588 toxic effect Effects 0.000 claims abstract description 8
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 230000005764 inhibitory process Effects 0.000 claims abstract description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 101150078369 rpsB gene Proteins 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 208000001860 Eye Infections Diseases 0.000 claims description 3
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 3
- 238000011109 contamination Methods 0.000 claims description 3
- 239000000645 desinfectant Substances 0.000 claims description 3
- 208000011323 eye infectious disease Diseases 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 206010048685 Oral infection Diseases 0.000 claims description 2
- 101100455520 Streptomyces lasalocidi lsd19 gene Proteins 0.000 claims description 2
- 101150037483 bkdA gene Proteins 0.000 claims description 2
- -1 fda Proteins 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 101150078665 lasB gene Proteins 0.000 claims description 2
- 101150084945 pdhA gene Proteins 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000002689 soil Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 101100447530 Dictyostelium discoideum gpi gene Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 101100120969 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) pgi1 gene Proteins 0.000 claims 1
- 208000037815 bloodstream infection Diseases 0.000 claims 1
- 101150053253 pgi gene Proteins 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 13
- 230000012010 growth Effects 0.000 abstract description 6
- 239000003550 marker Substances 0.000 description 111
- 239000013612 plasmid Substances 0.000 description 89
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 64
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 52
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 43
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 43
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 43
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 43
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 43
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 43
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 43
- 230000000295 complement effect Effects 0.000 description 41
- 238000010586 diagram Methods 0.000 description 39
- 239000000047 product Substances 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 37
- 241000588724 Escherichia coli Species 0.000 description 37
- 238000012239 gene modification Methods 0.000 description 35
- 238000010276 construction Methods 0.000 description 34
- 101150066555 lacZ gene Proteins 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 102100036407 Thioredoxin Human genes 0.000 description 26
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 25
- 102100026189 Beta-galactosidase Human genes 0.000 description 24
- 108010005774 beta-Galactosidase Proteins 0.000 description 24
- 239000002609 medium Substances 0.000 description 23
- 239000013598 vector Substances 0.000 description 22
- BUAQBZPEZUPDRF-RHQZKXFESA-N (2r,3r,4r,5r,6s)-2-(hydroxymethyl)-6-[(2-hydroxy-7,8,9,10-tetrahydro-6h-benzo[c]chromen-3-yl)oxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1C(CCCC1)=C1CO2 BUAQBZPEZUPDRF-RHQZKXFESA-N 0.000 description 20
- 230000021615 conjugation Effects 0.000 description 18
- 238000011144 upstream manufacturing Methods 0.000 description 17
- 239000004098 Tetracycline Substances 0.000 description 15
- 230000006801 homologous recombination Effects 0.000 description 15
- 238000002744 homologous recombination Methods 0.000 description 15
- 101150009573 phoA gene Proteins 0.000 description 15
- 229960002180 tetracycline Drugs 0.000 description 15
- 229930101283 tetracycline Natural products 0.000 description 15
- 235000019364 tetracycline Nutrition 0.000 description 15
- 150000003522 tetracyclines Chemical class 0.000 description 15
- 108091005899 fibrous proteins Proteins 0.000 description 14
- 102000034240 fibrous proteins Human genes 0.000 description 14
- 230000007505 plaque formation Effects 0.000 description 14
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 230000003389 potentiating effect Effects 0.000 description 12
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 241000194107 Bacillus megaterium Species 0.000 description 10
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 108091029795 Intergenic region Proteins 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 101150026476 PAO1 gene Proteins 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 230000013011 mating Effects 0.000 description 8
- 230000019612 pigmentation Effects 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000002887 multiple sequence alignment Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 101150025220 sacB gene Proteins 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- 101100004352 Escherichia coli lacZ gene Proteins 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000013602 bacteriophage vector Substances 0.000 description 4
- 230000002457 bidirectional effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000002925 A-like Anatomy 0.000 description 3
- 108020000946 Bacterial DNA Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- 208000032536 Pseudomonas Infections Diseases 0.000 description 3
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000017066 negative regulation of growth Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000001066 phage therapy Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000004708 ribosome subunit Anatomy 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 241000589291 Acinetobacter Species 0.000 description 2
- 101100465058 Caenorhabditis elegans prk-2 gene Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241001126663 Escherichia virus K1-5 Species 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 101100433970 Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) ACE1 gene Proteins 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 101710192508 30S ribosomal protein S2 Proteins 0.000 description 1
- 101000870242 Bacillus phage Nf Tail knob protein gp9 Proteins 0.000 description 1
- 108700023313 Bacteriophage Receptors Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108050006183 Pyruvate dehydrogenase E1 component Proteins 0.000 description 1
- 102000026183 Pyruvate dehydrogenase E1 component Human genes 0.000 description 1
- 101150075200 S-2 gene Proteins 0.000 description 1
- 101150018840 SPM1 gene Proteins 0.000 description 1
- 101100335888 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GAL83 gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 101150031187 fba gene Proteins 0.000 description 1
- 101150108901 fbaA gene Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001374 post-anti-biotic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 101150100021 soxR gene Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
- C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
- C12N2795/00045—Special targeting system for viral vectors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Soil Conditioners And Soil-Stabilizing Materials (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
(それぞれが複数の尾繊維を含有する個々のファージまたはファージ混合物における複数の尾繊維を含む遺伝子構築物)
溶菌性バクテリオファージを非溶菌性にして、および30Sリボソームサブユニットタンパク質S2遺伝子(rpsB)の発現を通常制御するプロモーターの制御下でSASP-Cに加えて、1つより多くの尾繊維遺伝子を有するようにする溶菌性バクテリオファージの遺伝子改変の概要。
クローニング目的でDNAを生成するためのPCR反応は、プライマーの融解温度(Tm)に応じて、Herculase II Fusion DNAポリメラーゼ(Agilent Technologies)を使用して、製造元の説明書に従って実施することができる。スクリーニング目的のPCR反応は、プライマーの融解温度(Tm)に応じて、Taq DNAポリメラーゼ(NEB)を使用して、製造元の説明書に従って実施することができる。特に明記していない限り、制限酵素消化、アガロースゲル電気泳動、T4 DNAリガーゼ依存的ライゲーション、コンピテント細胞の調製および形質転換などの一般的な分子生物学技術は、Sambrookら、(1989)に記述される方法に基づくことができる。酵素は、New England BiolabsまたはThermo Scientificから購入することができる。DNAは、酵素反応から精製して、Qiagen DNA精製キットを使用して細胞から調製することができる。プラスミドは、接合ヘルパー株である大腸菌HB101(pRK2013)によって媒介される接合によって大腸菌株から緑膿菌株に伝達することができる。β-ガラクトシダーゼの色素生成基質であるS-galはSigma(S9811)から購入することができ、これはβ-ガラクトシダーゼによる消化によって、鉄イオンとキレートを形成すると黒色の沈殿物を形成する。
1.実験的ファージ試料中のPhi33様ファージ様尾繊維遺伝子を検出するためのプライマーは、以下のように設計することができる。
1.緑膿菌PAO1 phoA相同体の3’末端に隣接するDNAを有するpSM1104を有するプラスミドpSMX400(図1)は以下のように構築することができる。
1.プラスミドpSMX401(図1)を接合によって緑膿菌に伝達して、テトラサイクリン(50μg/ml)に対する耐性の獲得によって一次組み換え体に関して選択することができる。
1.Phi33尾繊維遺伝子のすぐ下流の領域を有するpSM1080を含むpSMX402(図2)は、以下のように構築することができる。
1.プラスミドpSMX403(図2、図4)を、接合によって緑膿菌株PAX40に導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA40を得ることができる。
1.プラスミドpSMX404(図3、図4)を、接合により緑膿菌株PAX40に導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA41を得ることができる。
1.連続するorf60からorf57の配列(orf60もorf57も完全ではなかった)に及ぶPhi33の2.8kbの断片を含有するpSM1080を含むプラスミドpSMX405(図5)は、以下のように構築することができる。図5は、Phi33ゲノム由来の領域を増幅するために以下に記述されるオリゴヌクレオチドのプライミング部位を示す。
1.pSMX406(図5;図6)を緑膿菌株PML14に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA42を得ることができる。
1.pSMX407(図5;図7)を緑膿菌株PML14に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA43を得ることができる。
1.pSMX407(図5;図8)を緑膿菌株PML14に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA43を得ることができる。
1.Phi33尾繊維遺伝子を有するpSMX405からなるプラスミドpSMX408(図5)は以下のように構築することができる。
1.pSMX408(図5;図6)を緑膿菌株PML14に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA44を得ることができる。
1.pSMX409(図5;図7;図8)を緑膿菌株PML14に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA45を得ることができる。
1.orf28~29遺伝子間領域に隣接するPhi33 DNAの配列を有するpSM1080を含むプラスミドpSMX410(図9)は以下のように構築することができる。
1.pSMX411(図9;図10)を緑膿菌株PML14に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA46を生成することができる。
1.ネイティブプロモーター(Porf57)の制御下で、Phi33(N)PTP47(C)尾繊維をコードする遺伝子を有するpSMX410を含むプラスミドpSMX412(図9)は、以下のように構築することができる。
1.pSMX412(図9;図10)を緑膿菌株PML14に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA47を得ることができる。
1.ネイティブエンドライシンプロモーターの制御下で、Phi33由来のエンドライシン遺伝子を有するpSMX400を含むプラスミドpSMX413(図1)は以下のように構築することができる。
1.プラスミドpSMX414を接合によって緑膿菌に伝達し、テトラサイクリン(50μg/ml)に対する耐性の獲得によって一次組み換え体に関して選択することができる。
1.エンドライシン遺伝子に隣接するPhi33の領域を含有するpSM1080を含むプラスミドpSMX415(図11)は、以下のように構築することができる。
1.プラスミドpSMX417(図11)を緑膿菌株PAX41に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA48を得ることができる。
1.プラスミドpSMX416(図11)を緑膿菌株PAX41に接合によって導入して、テトラサイクリン耐性(50μg/ml)に基づいて接合伝達体を選択し、株PTA49を得ることができる。
粗ファージ溶解物10μlを、細菌を接種した軟寒天重層プレート上に滴下することによって、株を各ファージに対する感受性に関して試験した。プレートを32℃で一晩増殖させて、接種点でのクリアランスゾーンを評価することによって、株を各ファージに対する感受性に関して採点した。ファージが、菌叢のクリアランスによって認められるように増殖を阻害した場合、株を感受性(+)と記し、増殖の阻害が認められない場合、株を非感受性(-)と記した。
Abedon ST.(2008).Bacteriophage Ecology:Population Growth,Evolution,an Impact of Bacterial Viruses.Cambridge.Cambridge University Press.Chapter 1.
Boucher,H.W.,Talbot,G.H.,Bradley,J.S.,Edwards,J.E.,Gilbert,D.,Rice,L.B.,& Bartlett,J.(2009).Bad bugs,no drugs:no ESKAPE! An update from the Infectious Diseases Society of America.Clinical Infectious Diseases,48:1-12.
Burrowes,B.,& Harper,D.R.(2012).14 Phage Therapy of Non-wound Infections. Bacteriophages in Health and Disease: Bacteriophages in Health and Disease,203.
Carlton,R.M.(1999).Phage therapy:past history and future prospects. Archivum Immunologiae et Therapiae Experimentalis-English Edition 47:267-274.
Ceyssens P,Miroshnikov K,Mattheus W,Krylov V,Robben J,Noben J,Vanderschraeghe S,Sykilinda N,Kropinski AM,Volckaert G,Mesyanzhinov V,Lavigne R.(2009).Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa.Env.Microbiol..11:2874-2883.
Francesconi,S.C.,MacAlister,T.J.,Setlow,B.,& Setlow,P.(1988).Immunoelectron microscopic localization of small, acid-soluble spore proteins in sporulating cells of Bacillus subtilis.J Bacteriol.,170:5963-5967.
Frenkiel-Krispin,D.,Sack,R.,Englander,J.,Shimoni,E.,Eisenstein,M.,Bullitt,E.& Wolf,S.G.(2004).Structure of the DNA-SspC complex: implications for DNA packaging, protection, and repair in bacterial spores.J.Bacteriol.186:3525-3530.
Gill JJ,Hyman P.(2010).Phage Choice, Isolation and Preparation for Phage therapy.Current Pharmaceutical Biotechnology.11:2-14.
Kutateladze,M.,& Adamia,R.(2010).Bacteriophages as potential new therapeutics to replace or supplement antibiotics.Trends Biotechnol.28:591-595.
Lee,K.S.,Bumbaca,D.,Kosman,J.,Setlow,P.,& Jedrzejas,M.J.(2008).Structure of a protein-DNA complex essential for DNA protection in spores of Bacillus species.Proc.Natl.Acad.Sci.105:2806-2811.
Nicholson WL,Setlow B,Setlow P.(1990).Binding of DNA in vitro by a small,acid-soluble spore protein from Bacillus subtilis and the effect of this binding on DNA topology.J Bacteriol.172:6900-6906.
Rakhuba DV,Kolomiets EI,Szwajcer Dey E,Novik EI.(2010).Bacteriophage Receptors,Mechanisms of Phage Adsorption and Penetration into Host Cell.Polish J.Microbio..59:145-155.
Sambrook,J.,Fritsch,E.F.,& Maniatis,T.(1989).Molecular cloning(Vol.2,pp.14-9).New York:Cold Spring Harbor Laboratory Press.
Scholl,D.,Rogers,S.,Adhya,S.,& Merril,C.R.(2001).Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli.J.Virol.75:2509-2515.
Veesler D,Cambillau C.(2011).A Common Evolutionary Origin for Tailed-Bacteriophage Functional Modules and Bacterial Machineries.Microbiol Mol Biol Rev.75:423-433.
Walker,B.,Barrett,S.,Polasky,S.,Galaz,V.,Folke,C.,Engstrom,G.,& de Zeeuw,A.(2009).Looming global-scale failures and missing institutions.Science,325:1345-1346.
世界保健機構(WHO)の2014年の抗菌剤耐性に関する地球規模調査報告書(WHO(2014)Antimicrobial resistance:global report on surveillance 2014.)
Claims (18)
- 標的細菌に対して毒性である低分子酸可溶性芽胞タンパク質(SASP)をコードするα/β型SASP遺伝子を含む、複数の異なる標的細菌に感染することができる改変バクテリオファージであって、
非溶菌性であり、
複数の異なる宿主域決定因子を発現し、
各宿主域決定因子が異なる細菌宿主特異性を有し、
各宿主域決定因子は、標的細菌に結合するための受容体結合領域と、受容体結合領域をバクテリオファージのボディに結合させる領域とを含む尾繊維タンパク質を含み、かつ、
受容体結合領域が、C末端受容体結合領域であり、C末端受容体結合領域をバクテリオファージのボディに結合させる領域がN末端領域である、改変バクテリオファージ。 - 宿主域決定因子の細菌宿主特異性が同じ細菌種に存在する、請求項1に記載の改変バクテリオファージ。
- 不活化された溶菌遺伝子、または、SASP遺伝子、SASP-CであるSASP遺伝子、もしくはバチルス・メガテリウム(Bacillus megaterium)由来であるSASP-Cの挿入によって不活化された溶菌遺伝子を含む、請求項1または請求項2に記載の改変バクテリオファージ。
- SASP遺伝子が、
構成的プロモーター、改変バクテリオファージが標的細菌において複数のコピーで存在する場合、毒性レベルのSASPの産生を促進するために十分に強いプロモーター、および、pdhA、rpsB、pgi、fda、lasB、およびそれらに対して90%超の配列同一性を有するプロモーターから選択されるプロモーター
からなる群より選択される少なくとも1つのプロモーターの制御下にある、請求項1~3のいずれか1項に記載の改変バクテリオファージ。 - 標的細菌の少なくとも1つがシュードモナス(Pseudomonas)であるか、もしくは、
複数の異なる標的細菌が、複数の異なるシュードモナス細菌であり、および/または、
前記シュードモナス細菌が緑膿菌(Pseudomonas aeruginosa)を含む、請求項1~4のいずれか1項に記載の改変バクテリオファージ。 - 各宿主域決定因子が、複数の異なる感染部位からの、およびある範囲の抗生物質耐性表現型を含む、少なくとも35個超の臨床単離体のコレクションの50%超によって定義される広い宿主域を有する、請求項1~5のいずれか1項に記載の改変バクテリオファージ。
- N末端領域が、バクテリオファージPhi33のアミノ酸配列に基づいて、尾繊維タンパク質のアミノ酸1~628位を含み、C末端領域が、尾繊維タンパク質のアミノ酸629~964位を含み、および/または
C末端領域がバクテリオファージPhi33のC末端領域と96%以下のアミノ酸配列同一性を有する、請求項1~6のいずれか1項に記載の改変バクテリオファージ。 - C末端領域がバクテリオファージPhi33、LBL3、SPM-1、F8、PB1、KPP12、LMA2、SN、14-1、JG024、NH4、PTP47、PTP92、C36、およびPTP93のいずれか1つに由来する、請求項7に記載の改変バクテリオファージ。
- C末端領域アミノ酸配列同一性が80%未満である、請求項8に記載の改変バクテリオファージ。
- N末端領域が、バクテリオファージPhi33のN末端領域と少なくとも95%のアミノ酸配列同一性を有する、請求項1~9のいずれか1項に記載の改変バクテリオファージ。
- N末端領域が、バクテリオファージPhi33、LBL3、SPM-1、F8、PB1、KPP12、LMA2、SN、14-1、JG024、NH4、PTP47、PTP92、C36、およびPTP93のいずれか1つに由来する、請求項10に記載の改変バクテリオファージ。
- 各尾繊維タンパク質が、Phi33、LBL3、SPM-1、F8、PB1、KPP12、LMA2、SN、14-1、JG024、NH4、PTP47、PTP92、C36、およびPTP93から選択されるバクテリオファージに由来する、請求項1~11のいずれか1項に記載の改変バクテリオファージ。
- 標的細菌に対して毒性であるSASPをコードするSASP遺伝子を含み、非溶菌性である、標的細菌に感染することができる少なくとも1つの他の改変バクテリオファージの混合物中の請求項1~12のいずれか1項に記載の改変バクテリオファージ。
- 薬剤として使用するための、請求項1~13のいずれか1項に記載の改変バクテリオファージ。
- 細菌感染症、または、
局所臓器感染症もしくは多臓器感染症を含む細菌感染症、または
局所感染症、経口感染症、呼吸器感染症、眼の感染症、もしくは血流中の感染症を含む細菌感染症の治療、および/または
前記感染症のヒトのための治療に使用するための、請求項1~14のいずれか1項に記載の改変バクテリオファージ。 - 細菌細胞増殖の治療的阻害または予防に使用するための、請求項1~13のいずれか1項に記載の改変バクテリオファージ。
- 請求項1~13のいずれか1項に記載の改変バクテリオファージとその担体とを含む、細菌細胞増殖を阻害または予防するための組成物;
薬学的使用のために調製される前記組成物;または、
局所使用のために調製される前記組成物。 - 請求項1~13のいずれか1項に記載の改変バクテリオファージを含む、表面細菌汚染の処理、土壌改良、または水の処理における除菌剤。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1417808.1 | 2014-10-08 | ||
GBGB1417808.1A GB201417808D0 (en) | 2014-10-08 | 2014-10-08 | Modified bacteriophage |
PCT/EP2015/073293 WO2016055584A1 (en) | 2014-10-08 | 2015-10-08 | Multiple host range bacteriophage with different tail fibres |
JP2017518837A JP2017537608A (ja) | 2014-10-08 | 2015-10-08 | 異なる尾繊維を有する複数宿主域のバクテリオファージ |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017518837A Division JP2017537608A (ja) | 2014-10-08 | 2015-10-08 | 異なる尾繊維を有する複数宿主域のバクテリオファージ |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022058377A true JP2022058377A (ja) | 2022-04-12 |
Family
ID=51947054
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017518837A Pending JP2017537608A (ja) | 2014-10-08 | 2015-10-08 | 異なる尾繊維を有する複数宿主域のバクテリオファージ |
JP2021206315A Pending JP2022058377A (ja) | 2014-10-08 | 2021-12-20 | 異なる尾繊維を有する複数宿主域のバクテリオファージ |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017518837A Pending JP2017537608A (ja) | 2014-10-08 | 2015-10-08 | 異なる尾繊維を有する複数宿主域のバクテリオファージ |
Country Status (7)
Country | Link |
---|---|
US (1) | US11236306B2 (ja) |
EP (1) | EP3201324A1 (ja) |
JP (2) | JP2017537608A (ja) |
AU (1) | AU2015329957B2 (ja) |
CA (1) | CA2963955A1 (ja) |
GB (1) | GB201417808D0 (ja) |
WO (1) | WO2016055584A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201417808D0 (en) | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modified bacteriophage |
GB201417805D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifield bacteriophage |
JP7166244B2 (ja) | 2016-04-08 | 2022-11-07 | フィコ セラピューティクス リミテッド | 改変バクテリオファージ |
LT3440200T (lt) * | 2016-04-08 | 2021-05-25 | Phico Therapeutics Ltd | Modifikuotas bakteriofagas |
AU2019208460A1 (en) * | 2018-01-19 | 2020-09-03 | Cytophage Technologies Inc. | Genetically engineered bacteriophage |
US11572595B2 (en) | 2018-12-31 | 2023-02-07 | Roche Molecular Systems, Inc. | Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002007742A2 (en) * | 2000-07-25 | 2002-01-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacteriophage having multiple host range |
WO2004113375A2 (en) * | 2003-06-20 | 2004-12-29 | Phico Therapeutics Limited | Antimicrobial compositions and uses thereof |
JP2010535482A (ja) * | 2007-08-07 | 2010-11-25 | フィコ セラピューティクス リミテッド | 改変バクテリオファージ |
JP2013545460A (ja) * | 2010-11-08 | 2013-12-26 | アビッドバイオティクス コーポレイション | 組換えp4バクテリオファージおよびその使用方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0028130D0 (en) | 2000-11-17 | 2001-01-03 | Phico Therapeutics Ltd | Polypeptide and uses thereof |
WO2003076583A2 (en) | 2002-03-06 | 2003-09-18 | Musc Foundation For Research Development | Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria |
GB201417808D0 (en) | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modified bacteriophage |
GB201417805D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifield bacteriophage |
-
2014
- 2014-10-08 GB GBGB1417808.1A patent/GB201417808D0/en not_active Ceased
-
2015
- 2015-10-08 AU AU2015329957A patent/AU2015329957B2/en active Active
- 2015-10-08 CA CA2963955A patent/CA2963955A1/en active Pending
- 2015-10-08 JP JP2017518837A patent/JP2017537608A/ja active Pending
- 2015-10-08 WO PCT/EP2015/073293 patent/WO2016055584A1/en active Application Filing
- 2015-10-08 EP EP15775719.6A patent/EP3201324A1/en active Pending
- 2015-10-08 US US15/517,656 patent/US11236306B2/en active Active
-
2021
- 2021-12-20 JP JP2021206315A patent/JP2022058377A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002007742A2 (en) * | 2000-07-25 | 2002-01-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacteriophage having multiple host range |
WO2004113375A2 (en) * | 2003-06-20 | 2004-12-29 | Phico Therapeutics Limited | Antimicrobial compositions and uses thereof |
JP2010535482A (ja) * | 2007-08-07 | 2010-11-25 | フィコ セラピューティクス リミテッド | 改変バクテリオファージ |
JP2013545460A (ja) * | 2010-11-08 | 2013-12-26 | アビッドバイオティクス コーポレイション | 組換えp4バクテリオファージおよびその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2015329957A9 (en) | 2019-08-01 |
CA2963955A1 (en) | 2016-04-14 |
AU2015329957B2 (en) | 2021-11-25 |
JP2017537608A (ja) | 2017-12-21 |
US11236306B2 (en) | 2022-02-01 |
US20170306298A1 (en) | 2017-10-26 |
EP3201324A1 (en) | 2017-08-09 |
GB201417808D0 (en) | 2014-11-19 |
WO2016055584A9 (en) | 2019-01-31 |
AU2015329957A1 (en) | 2017-04-20 |
WO2016055584A1 (en) | 2016-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022058377A (ja) | 異なる尾繊維を有する複数宿主域のバクテリオファージ | |
JP7141756B2 (ja) | 異なる尾繊維を有する複数宿主域のバクテリオファージ | |
ES2768773T3 (es) | Modificación de bacteriófagos | |
JP7051809B2 (ja) | 改変バクテリオファージ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220112 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20220329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230516 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230621 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231006 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231207 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240319 |